Key result
Aspirin monotherapy shows no cardiovascular benefit over clopidogrel beyond one month post-PCI in diabetes.
Why the study?
Does aspirin monotherapy compared to clopidogrel monotherapy improve cardiovascular and bleeding outcomes in patients with diabetes beyond 1 month after percutaneous coronary intervention?
RCT (n=5,833)
Open-label
1:1
Yes
Does aspirin monotherapy compared to clopidogrel monotherapy improve cardiovascular and bleeding outcomes in patients with diabetes beyond 1 month after percutaneous coronary intervention?
In patients with diabetes, aspirin monotherapy and clopidogrel monotherapy beyond 1 month after PCI showed similar cardiovascular outcomes, though aspirin may be associated with a higher bleeding risk.
No takes yet. Share an insight, caveat, or question.
Either monotherapy is acceptable beyond 1 month post-PCI in diabetes; extends overall trial results to this subgroup.
No abstract yet. The journal hasn't published one we can show.
Kanenawa et al. (2026) conducted an RCT in Coronary artery disease with diabetes undergoing percutaneous coronary intervention (n=5,833). Aspirin monotherapy vs. Clopidogrel monotherapy (75 mg/day) was evaluated on Coprimary cardiovascular endpoint (composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke) in patients with diabetes (HR 0.96, 95% CI 0.67-1.37). Aspirin monotherapy compared with clopidogrel monotherapy beyond 1 month after PCI resulted in similar cardiovascular outcomes in patients with diabetes (HR 0.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: